Prevalence and clinical relevance of T-helper cells, Th17 and Th1, in hepatitis B virus-related hepatocellular carcinoma

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Yan, Jian ^a   Liu, Xiao Long ^a   Xiao, Gang ^a   Li, Ning Lei ^a   Deng, Yi Nan ^b,c   Han, Lu Zhe ^a   Yin, Liang Chun ^a   Ling, Li Juan ^a   Liu, Li Xin ^a  

^a THE THIRD AFFILIATED HOSPITAL OF SOUTHERN MEDICAL UNIVERSITY   (China)

^b Guangdong Provincial Key Laboratory of Liver Disease Research   (China)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 17; CYTOKINE;

ARTICLE; BLOOD SAMPLING; CANCER PROGNOSIS; CELL DENSITY; CELLULAR IMMUNITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DISEASE SEVERITY; FLOW CYTOMETRY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PHENOTYPE; PREVALENCE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TH1 CELL; TH17 CELL; TUMOR GROWTH; CASE CONTROL STUDY; COMPARATIVE STUDY; DISEASE COURSE; ENZYME IMMUNOASSAY; FOLLOW UP; HELPER CELL; IMMUNOLOGY; ISOLATION AND PURIFICATION; LIVER TUMOR; METABOLISM; MORTALITY; PROGNOSIS; REGULATORY T LYMPHOCYTE; SURVIVAL RATE; VIROLOGY;

CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CYTOKINES; DISEASE PROGRESSION; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; IMMUNOENZYME TECHNIQUES; INTERLEUKIN-17; LIVER NEOPLASMS; PROGNOSIS; SURVIVAL RATE; T-LYMPHOCYTES, HELPER-INDUCER; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TH17 CELLS;

EID: 84901448355     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0096080     Document Type: Article

References (42)

1. Schwartz M, Roayaie S, Konstadoulakis M (2007) Strategies for the management of hepatocellular carcinoma. Nat Clin Prac Oncol 4: 424-432. (Pubitemid 47039693)
2. Yu MW, Chang HC, Chen CJ (2002) Increased risk for hepatitis B-related liver cirrhosis in relatives of patients with hepatocellular carcinoma in northern Taiwan. Int J Epidemiol 31: 1008-1015.
3. Semela D, Dufour JF (2004) Angiogenesis and hepatocellular carcinoma. J Hepatol 41: 864-880. (Pubitemid 39434320)
4. Mueller MM, Fusenig NE (2004) Friends or foes-bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 4: 839-849. (Pubitemid 39472951)
5. Budhu A, Forgues M, Ye QH, Jia HL, He P, et al. (2006) Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 10: 99-111. (Pubitemid 44202603)
6. Parkin D, Pisani P, Munoz N, Ferlay J (1999) Cold Spring Harbor. NY: Cold Spring Harbor Laboratory Press.
7. Gulumian M (1999) The role of oxidative stress in diseases caused by mineral dusts and fibres: current status and future of prophylaxis and treatment. Mol Cell Biochem 196: 69.
8. Negus RP, Stamp GW, Hadley J, Balkwill FR (1997) Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am J Pathol 150: 1723.
9. Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, et al. (2007) Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 25: 2586-2593. (Pubitemid 47041232)
10. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL (1986) Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 136: 2348.
11. Del Prete GF, De Carli M, Mastromauro C, Biagiotti R, Macchia D, et al. (1991) Purified protein derivative of Mycobacterium tuberculosis and excretory-secretory antigen(s) of Toxocara canis expand in vitro human T cells with stable and opposite (type 1 T helper or type 2 T helper) profile of cytokine production. J Clin Invest 88: 346-350.
12. Mosmann TR, Sad S (1996) The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 17: 138.
13. Zou W (2005) Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5: 263-274.
14. Gajewski TF (2007) The expanding universe of regulatory T cell subsets in cancer. Immunity 27: 185-187.
15. Wang HY, Wang RF (2007) Regulatory T cells and cancer. Curr Opin Immuno 19: 217-223. (Pubitemid 46356965)
16. Harrington LE, Mangan PR, Weaver CT (2006) Expanding the effector CD4 Tcell repertoire: the Th17 lineage. Curr Opin Immunol 18: 349.
17. Park H, Li Z, Yang XO, Chang SH, Nurieva R, et al. (2005) A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 6: 1133-1141. (Pubitemid 41541791)
18. Weaver CT, Hatton RD, Mangan PR, Harrington LE (2007) IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 25: 821-852. (Pubitemid 46697925)
19. Kolls JK, Linden A (2004) Interleukin-17 family members and inflammation. Immunity 21: 467-476. (Pubitemid 39370503)
20. Dong C (2008) TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol 8: 337-348.
21. Stockinger B, Veldhoen M (2007) Differentiation and function of Th17 T cells. Curr Opin Immunol 19: 281-286. (Pubitemid 46687011)
22. Ge J, Wang K, Meng QH, Qi ZX, Meng FL, et al. (2010) Implication of Th17 and Th1 cells in patients with chronic active hepatitis B. J Clin Immunol 30: 60-67.
23. Zou W (2005) Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5: 263-274.
24. Yang XH, Yamagiwa S, Ichida T, Matsuda Y, Sugahara S, et al. (2006) Increase of CD4+CD25+ regulatory T-cells in the liver of patients with hepatocellular carcinoma. J Hepatol 45: 254-262.
25. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420: 860-867. (Pubitemid 36019639)
26. Lin WW, Karin M (2007) A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 117: 1175-1183.
27. Ouyang W, Kolls JK, Zheng Y (2008) The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 28: 454-467. (Pubitemid 351471762)
28. Dong C (2008) Regulation and pro-inflammatory function of interleukin-t7 family cytokines. Inmlunol Rev 226: 80-86.
29. Kryczek I, Wei S, Zou L, Altuwaijri S, Szeliga W, et al. (2007) Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol 178: 6730-6733. (Pubitemid 46847396)
30. Tartour E, Fossiez F, Joyeux I, Galinha A, Gey A, et al. (1999) Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res 59: 3698-3704. (Pubitemid 29381875)
31. Langowski JL, Zhang X, Wu L, Mattson JD, Chen T, et al. (2006) IL-23 promotes tumour incidence and growth. Nature 442: 461-465. (Pubitemid 44264796)
32. Numasaki M, Fukushi J, Ono M, Narula SK, Zavodny PJ, et al. (2003) Interleukin-17 promotes angiogenesis and tumor growth. Blood 101: 2620- 2627.
33. Benchetrit F, Ciree A, Vives V, Warnier G, Gey A, et al. (2002) Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood 99: 2114-2121. (Pubitemid 34525496)
34. Muranski P, Boni A, Antony PA, Cassard L, Irvine KR, et al. (2008) Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 112: 362-373.
35. Mantovani A, Romero P, Palucka AK, Marincola FM (2008) Tumour immunity: effector response to tumour and role of the microenvironment. Lancet 371: 771-783.
36. Kennedy R, Celis E (2008) Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunol Rev 222: 129-144. (Pubitemid 351430378)
37. Jung MC, Pape GR (2002) Immunology of hepatitis B infection. Lancet Infect Dis 2: 43-50.
38. Dunn GP, Koebel CM, Schreiber RD (2006) Interferons, immunity and cancer immunoediting. Nat Rev Immunol 6: 836-848. (Pubitemid 44631652)
39. Annunziato F, Cosmi L, Santarlasci V, Maggi L, Liotta F, et al. (2007) Phenotypic and functional features of human Th17 cells. J Exp Med 204: 1849- 1861.
40. Rowan AG, Fletcher JM, Ryan EJ, Moran B, Hegarty JE, et al. (2008) Hepatitis C virus specific Thl7 cells are suppressed by virus-induced TGF- β. J Immunol 181: 4485-4494.
41. Zhang JY, Zhang Z, Wang FS, Zou ZS, Xu RN, et al. (2010) Interleukin-17-producing CD4(+) T cells increase with severity of liver damage in patients with chronic hepatitis B. Hepatology 51: 81-91.
42. Jimenez-Sousa MA, Almansa R, de La Fuente C, Caro-Paton A, Ruiz L, et al. (2010) Increased Thl, Thl7 and pro-fibrotic responses in hepatitis C infected patients are down-regulated after 12 weeks of treatment with pegylated interferon plus ribavirin. Eur Cytokine Netw 21: 84-91.